JPWO2022236292A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022236292A5
JPWO2022236292A5 JP2023568310A JP2023568310A JPWO2022236292A5 JP WO2022236292 A5 JPWO2022236292 A5 JP WO2022236292A5 JP 2023568310 A JP2023568310 A JP 2023568310A JP 2023568310 A JP2023568310 A JP 2023568310A JP WO2022236292 A5 JPWO2022236292 A5 JP WO2022236292A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
optionally
linker
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517871A (ja
JP2024517871A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072121 external-priority patent/WO2022236292A2/en
Publication of JP2024517871A publication Critical patent/JP2024517871A/ja
Publication of JPWO2022236292A5 publication Critical patent/JPWO2022236292A5/ja
Publication of JP2024517871A5 publication Critical patent/JP2024517871A5/ja
Pending legal-status Critical Current

Links

JP2023568310A 2021-05-07 2022-05-05 プロテアーゼ活性化治療剤を含む組成物および方法 Pending JP2024517871A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163185941P 2021-05-07 2021-05-07
US63/185,941 2021-05-07
US202263313087P 2022-02-23 2022-02-23
US63/313,087 2022-02-23
PCT/US2022/072121 WO2022236292A2 (en) 2021-05-07 2022-05-05 Compositions and methods comprising protease-activated therapeutic agents

Publications (3)

Publication Number Publication Date
JP2024517871A JP2024517871A (ja) 2024-04-23
JPWO2022236292A5 true JPWO2022236292A5 (https=) 2025-05-15
JP2024517871A5 JP2024517871A5 (https=) 2025-05-15

Family

ID=83932456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568310A Pending JP2024517871A (ja) 2021-05-07 2022-05-05 プロテアーゼ活性化治療剤を含む組成物および方法

Country Status (4)

Country Link
US (1) US20240228586A1 (https=)
EP (1) EP4333873A4 (https=)
JP (1) JP2024517871A (https=)
WO (1) WO2022236292A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
CR20250279A (es) * 2023-01-20 2025-08-25 Boehringer Ingelheim Int Proteínas de fusión fc de il-12
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517934A (ja) * 2008-03-03 2011-06-23 カンザス ステイト ユニバーシティ リサーチ ファウンデーション プロテアーゼアッセイ
TWI759810B (zh) * 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
CA3100005A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
US20220356221A1 (en) * 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs

Similar Documents

Publication Publication Date Title
JPWO2021016640A5 (https=)
Svenson et al. Specific binding of interleukin 1 (IL-1) β and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I
US20200048331A1 (en) Immunoregulatory structures from normally occuring proteins
WO2021092075A1 (en) IL-2RβγC BINDING COMPOUNDS
CA2289912A1 (en) Human receptor proteins; related reagents and methods
CA2386463A1 (en) April receptor (bcma) and uses thereof
US20220098274A1 (en) Engineered pd-1 variants
JP2020508691A5 (https=)
CN110662560A (zh) 改进的抗原结合受体
RU2010121967A (ru) Белковые каркасные структуры
WO2009142773A4 (en) Multivalent fibronectin based scaffold domain proteins
Kufer et al. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
CA2561826A1 (en) Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody
JP2023536169A (ja) 改善された抗原結合受容体
Avery et al. Characterization of factor H binding to human polymorphonuclear leukocytes.
KR20220093323A (ko) HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
KR20240111753A (ko) 개선된 항원 결합 수용체
JPWO2022236292A5 (https=)
CN119278052A (zh) 预防或减轻与t细胞接合剂相关的不良反应
US20260103528A1 (en) Nanobodies that bind to gprc5d and uses thereof
AU672967B2 (en) Polypeptides with fibronectin binding sites as modulators for matrix assembly
EP4547708A1 (en) Fusion proteins with half life extending domains
CN119731199A (zh) 工程化的白细胞介素-2受体β降低结合的激动剂
Reiser et al. Peptide-specific antibodies indicate species heterogeneity of a 42-kDa high-affinity inositol 1, 3, 4, 5-tetrakisphosphate receptor protein from brain
JPWO2022190016A5 (https=)